Beiersdorf Aktiengesellschaft Q4 Earnings Call Highlights
View original at finance.yahoo.comBeiersdorf Aktiengesellschaft Q4 Earnings Call Highlights Beiersdorf Aktiengesellschaft logo Beiersdorf Aktiengesellschaft (ETR:BEI) management said the company delivered “stable” full-year 2025 results in a difficult operating backdrop, while outlining steps to restore momentum at its largest brand, NIVEA, and reaffir…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The luxury market remains highly volatile with persistent weakness in the U.S. and travel retail
80% confidenceNIVEA Cellular Epigenetic Serum was the strongest NIVEA face care rollout in history
80% confidenceThe global skincare market slowed materially, decelerating from mid-single-digit growth in 2024 to roughly 1.5% to 2% in 2025
80% confidenceIndia, domestic China and Japan were cited as white spaces for Derma expansion
80% confidenceMarket dynamics had not improved at the start of 2026
80% confidenceBeiersdorf delivered stable full-year 2025 results in a difficult operating backdrop
80% confidenceEucerin Thiamidol Serum became the number one derma anti-pigment serum in China
80% confidenceConsumers became more cautious and increasingly selective in their routines
80% confidenceThe shift is primarily a reallocation of spending away from premium face care into body care, deodorants and affordable skincare, which are much less media intensive
80% confidenceLa Prairie's Q1 2026 performance would be down double digits
80% confidenceNIVEA Cellular Epigenetic Serum remains the number one serum across Europe
80% confidenceBeiersdorf would not reduce marketing investment proportionally despite margin pressure
80% confidenceEmployee safety was the top priority regarding Middle East volatility and it was too early to assess any potential business impact
80% confidenceBeiersdorf maintained its position as the best performing skincare company globally for the third year in a row
80% confidenceNIVEA's 2025 performance fell short of expectations due to market slowdown, China repositioning, and major innovations concentrated in second half
80% confidenceCash conversion was weaker than hoped and working capital rose above 10% of sales
80% confidence